377 related articles for article (PubMed ID: 34105205)
1. Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives.
Gatto L; Franceschi E; Di Nunno V; Tosoni A; Lodi R; Brandes AA
Oncologist; 2021 Oct; 26(10):865-878. PubMed ID: 34105205
[TBL] [Abstract][Full Text] [Related]
2. Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas.
Tabibkhooei A; Izadpanahi M; Arab A; Zare-Mirzaei A; Minaeian S; Rostami A; Mohsenian A
Clin Neurol Neurosurg; 2020 Mar; 190():105652. PubMed ID: 31896490
[TBL] [Abstract][Full Text] [Related]
3. The Role of Circulating MicroRNA in Glioblastoma Liquid Biopsy.
Garcia CM; Toms SA
World Neurosurg; 2020 Jun; 138():425-435. PubMed ID: 32251831
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.
Szopa W; Burley TA; Kramer-Marek G; Kaspera W
Biomed Res Int; 2017; 2017():8013575. PubMed ID: 28316990
[TBL] [Abstract][Full Text] [Related]
5. Serum miR-100 is a potential biomarker for detection and outcome prediction of glioblastoma patients.
Zhang H; Wang J; Wang Z; Ruan C; Wang L; Guo H
Cancer Biomark; 2019; 24(1):43-49. PubMed ID: 30530966
[TBL] [Abstract][Full Text] [Related]
6. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
[TBL] [Abstract][Full Text] [Related]
7. Circulating microRNA-137 is a potential biomarker for human glioblastoma.
Li HY; Li YM; Li Y; Shi XW; Chen H
Eur Rev Med Pharmacol Sci; 2016 Sep; 20(17):3599-604. PubMed ID: 27649660
[TBL] [Abstract][Full Text] [Related]
8. Self-Functionalized Superlattice Nanosensor Enables Glioblastoma Diagnosis Using Liquid Biopsy.
Premachandran S; Haldavnekar R; Ganesh S; Das S; Venkatakrishnan K; Tan B
ACS Nano; 2023 Oct; 17(20):19832-19852. PubMed ID: 37824714
[TBL] [Abstract][Full Text] [Related]
9. Strategies, considerations, and recent advancements in the development of liquid biopsy for glioblastoma: a step towards individualized medicine in glioblastoma.
Bauman MMJ; Bouchal SM; Monie DD; Aibaidula A; Singh R; Parney IF
Neurosurg Focus; 2022 Dec; 53(6):E14. PubMed ID: 36455271
[TBL] [Abstract][Full Text] [Related]
10. Sonobiopsy for minimally invasive, spatiotemporally-controlled, and sensitive detection of glioblastoma-derived circulating tumor DNA.
Pacia CP; Yuan J; Yue Y; Xu L; Nazeri A; Desai R; Gach HM; Wang X; Talcott MR; Chaudhuri AA; Dunn GP; Leuthardt EC; Chen H
Theranostics; 2022; 12(1):362-378. PubMed ID: 34987650
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.
Schäfer N; Gielen GH; Rauschenbach L; Kebir S; Till A; Reinartz R; Simon M; Niehusmann P; Kleinschnitz C; Herrlinger U; Pietsch T; Scheffler B; Glas M
J Transl Med; 2019 Mar; 17(1):96. PubMed ID: 30894200
[TBL] [Abstract][Full Text] [Related]
12. Novel Molecular Markers in Glioblastoma-Benefits of Liquid Biopsy.
Birkó Z; Nagy B; Klekner Á; Virga J
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053907
[No Abstract] [Full Text] [Related]
13. Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients' management: Close to the clinic?
Simonelli M; Dipasquale A; Orzan F; Lorenzi E; Persico P; Navarria P; Pessina F; Nibali MC; Bello L; Santoro A; Boccaccio C
Crit Rev Oncol Hematol; 2020 Feb; 146():102879. PubMed ID: 32005411
[TBL] [Abstract][Full Text] [Related]
14. Exosomal long non-coding RNAs in glioblastoma.
Fattahi M; Alamdari-Palangi V; Rahimi Jaberi K; Ehtiati S; Ojaghi S; Rahimi-Jaberi A; Samavarchi Tehrani S; Dang P; Movahedpour A; Hossein Khatami S
Clin Chim Acta; 2024 Jan; 553():117705. PubMed ID: 38086498
[TBL] [Abstract][Full Text] [Related]
15. The post-surgical era of GBM: How molecular biology has impacted on our clinical management. A review.
Monticelli M; Zeppa P; Zenga F; Altieri R; Mammi M; Bertero L; Castellano I; Cassoni P; Melcarne A; La Rocca G; Sabatino G; Ducati A; Garbossa D
Clin Neurol Neurosurg; 2018 Jul; 170():120-126. PubMed ID: 29777944
[TBL] [Abstract][Full Text] [Related]
16. Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme-a retrospective cohort study.
Masood AB; Batool S; Bhatti SN; Ali A; Valko M; Jomova K; Kuca K
Front Immunol; 2023; 14():1202098. PubMed ID: 37529045
[TBL] [Abstract][Full Text] [Related]
17. Recent advances of the regulation roles of MicroRNA in glioblastoma.
Yan C; Kong X; Gong S; Liu F; Zhao Y
Int J Clin Oncol; 2020 Jul; 25(7):1215-1222. PubMed ID: 32347433
[TBL] [Abstract][Full Text] [Related]
18. Molecular and Circulating Biomarkers of Brain Tumors.
Jelski W; Mroczko B
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34210107
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs in glioblastoma: role in pathogenesis and opportunities for targeted therapies.
Costa PM; Cardoso AL; Mano M; de Lima MC
CNS Neurol Disord Drug Targets; 2015; 14(2):222-38. PubMed ID: 25613511
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs as biomarkers for human glioblastoma: progress and potential.
Huang SW; Ali ND; Zhong L; Shi J
Acta Pharmacol Sin; 2018 Sep; 39(9):1405-1413. PubMed ID: 29417946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
